

ASX RELEASE

19 December 2024

Results of Extraordinary General Meeting

Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to confirm that each of the resolutions put to its Extraordinary General Meeting held earlier today were <u>carried</u>.

Details of the results of the meeting are attached.

This ASX announcement is authorised for release by the Company Secretary.

- End -

Investor Contact: Dr Chris Burns Chief Executive Officer <u>chris@ampliatx.com</u> Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit <u>www.ampliatx.com</u> and follow Amplia on <u>Twitter</u> (@ampliatx), <u>Threads</u> (@ampliatx) and <u>LinkedIn</u>.

AMPLIA THERAPEUTICS LIMITED

Extraordinary General Meeting Thursday, 19 December 2024 Results of Meeting



The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

| Resolution details | | Instructions given to validly appointed proxies (as at proxy close) | | | | Number of votes cast on the poll (where applicable) | | | Resolution |
|---|--------------------|--|-----------|-----------------------|------------|--|-----------|------------|--------------------------|
| | Result | | | | | | | | |
| Resolution | Resolution Type | For | Against | Proxy's Discretion | Abstain | For | Against | Abstain* | Carried / Not Carried |
| 1 Ratification of Placement Shares | Ordinary | 125,751,824 | 830,879 | 3,072,494 | 26,441,848 | 128,824,318 | 830,879 | 26,441,848 | Carried |
| | | 96.99% | 0.64% | 2.37% | | 99.36% | 0.64% | | |
| 2 Issue of Attaching Options under the Placement | Ordinary | 125,521,809 | 1,043,994 | 3,089,394 | 26,441,848 | 128,611,203 | 1,043,994 | 26,441,848 | Carried |
| | | 96.81% | 0.81% | 2.38% | | 99.19% | 0.81% | | |
| 3 Issue of Lead Manager Options | Ordinary | 152,875,378 | 2,499,494 | 3,072,869 | 108,420 | 155,948,247 | 2,499,494 | 108,420 | Carried |
| | | 96.48% | 1.58% | 1.94% | | 98.42% | 1.58% | | |
| 4 Issue of Sub-Underwriter Options | Ordinary | 150,874,436 | 2,527,914 | 3,322,494 | 171,150 | 154,196,930 | 2,527,914 | 171,150 | Carried |
| | | 96.27% | 1.61% | 2.12% | | 98.39% | 1.61% | | |
| 5 Issue PLC Shares and Opt to Dr Warwick Tong | Ordinary | 151,727,535 | 672,900 | 3,072,494 | 3,083,232 | 154,800,029 | 672,900 | 3,083,232 | Carried |
| | | 97.59% | 0.43% | 1.98% | | 99.57% | 0.43% | | |
| 6 Issue PLC Shares and Opt to Dr Christopher Burns | Ordinary | 150,907,487 | 616,900 | 3,187,998 | 3,843,776 | 154,095,485 | 616,900 | 3,843,776 | Carried |
| | | 97.54% | 0.40% | 2.06% | | 99.60% | 0.40% | | |
| 7 Issue PLC Shares and Opt to Dr Robert Peach | Ordinary | 149,687,245 | 1,337,404 | 3,072,494 | 4,459,018 | 152,759,739 | 1,337,404 | 4,459,018 | Carried |
| | | 97.14% | 0.87% | 1.99% | | 99.13% | 0.87% | | |
| 8 Issue PLC Shares and Opt to Ms Jane Bell | Ordinary | 151,243,614 | 1,308,984 | 3,072,494 | 95,405 | 154,316,108 | 1,308,984 | 95,405 | Carried |
| | | 97.18% | 0.84% | 1.97% | | 99.16% | 0.84% | | |

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.